Publicaciones (58) Publicaciones de RAQUEL MUÑOZ MARTINEZ

2021

  1. Metronomic anti-cancer therapy: A multimodal therapy governed by the tumor microenvironment

    Cancers, Vol. 13, Núm. 21

2020

  1. A double safety lock tumor-specific device for suicide gene therapy in breast cancer

    Cancer Letters, Vol. 470, pp. 43-53

2019

  1. Self-Assembling ELR-Based Nanoparticles as Smart Drug-Delivery Systems Modulating Cellular Growth via Akt

    Biomacromolecules, Vol. 20, Núm. 5, pp. 1996-2007

  2. Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion

    PLoS ONE, Vol. 14, Núm. 9

2018

  1. A different approach for the analysis of grapes: Using the skin as sensing element

    Food Research International, Vol. 107, pp. 544-550

2014

  1. Electronic tongue formed by sensors and biosensors containing phthalocyanines as electron mediators:

    Journal of Porphyrins and Phthalocyanines, Vol. 18, Núm. 1-2, pp. 76-86

2013

  1. In vitro and in vivo effects of an anti-mouse endoglin (CD105)-immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumours

    Cancer Immunology, Immunotherapy, Vol. 62, Núm. 3, pp. 541-551

  2. Sensor arrays based on phthalocyanines: New developments on nanostructured and biomimetic electrochemical sensors

    Multisensor Systems for Chemical Analysis: Materials and Sensors (Pan Stanford Publishing Pte. Ltd.), pp. 139-179

2012

  1. Multisensor system based on bisphthalocyanine nanowires for the detection of antioxidants

    Electrochimica Acta, Vol. 68, pp. 88-94

  2. Transient injury-dependent up-regulation of CD105 and its specific targeting with an anti-vascular anti-mouse endoglin-nigrin b immunotoxin

    Medicinal Chemistry, Vol. 8, Núm. 6, pp. 996-1002

2008

  1. Metronomic antiangiogenic chemotherapy: Questions and answers

    Tumor Angiogenesis: Basic Mechanisms and Cancer Therapy (Springer Berlin Heidelberg), pp. 593-607

  2. Toxins as Transporting Tools

    Bacterial Toxins: Tools in Cell Biology and Pharmacology (wiley), pp. 273-294

2007

  1. On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing

    Cancer and Metastasis Reviews, Vol. 26, Núm. 3-4, pp. 737-747

  2. Targeting a marker of the tumour neovasculature using a novel anti-human CD105-immunotoxin containing the non-toxic type 2 ribosome-inactivating protein nigrin b

    Cancer Letters, Vol. 256, Núm. 1, pp. 73-80

2006

  1. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy

    Cancer Research, Vol. 66, Núm. 7, pp. 3386-3391

2005

  1. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy

    Breast, Vol. 14, Núm. 6, pp. 466-479

  2. Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose

    Current Cancer Drug Targets, Vol. 5, Núm. 7, pp. 551-559

  3. Cytotoxicity of an ebulin l-anti-human CD105 immunotoxin on mouse fibroblasts (L929) and rat myoblasts (L6E9) cells expressing human CD105.

    Medicinal chemistry, Vol. 1, Núm. 1, pp. 65-70

  4. Specific dose-dependent damage of Lieberkühn crypts promoted by large doses of type 2 ribosome-inactivating protein nigrin b intravenous injection to mice

    Toxicology and Applied Pharmacology, Vol. 207, Núm. 2, pp. 138-146

2003

  1. Evidence for distinct cellular internalization pathways of ricin and nigrin b.

    Cellular and molecular biology (Noisy-le-Grand, France), Vol. 49 Online Pub